Skip to main content
. 2022 Mar 15;132(6):e147908. doi: 10.1172/JCI147908

Figure 8. Model depicting the role of the NANOG/HDAC1 axis in resistance to anti–PD-1 therapy.

Figure 8

(A) NANOG drives immune refractoriness against anti–PD-1 therapy by blocking the antitumor immunity cycle. (B) Molecular pathway through which the NANOG/HDAC1 axis represses T cell infiltration of tumors and tumor cell death by CTL-mediated killing.